Zydus Lifesciences Ltd Stock Price Today (NSE: ZYDUSLIFE)
Fundamental Score
Zydus Lifesciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Zydus Lifesciences Ltd share price today is ₹1078.30, up +0.00% on NSE/BSE as of 20 July 2026. Zydus Lifesciences Ltd (ZYDUSLIFE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.15L (Cr). The 52-week high for ZYDUSLIFE share price is ₹1115.50 and the 52-week low is ₹835.50. At a P/E ratio of 21.26x, ZYDUSLIFE is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 21.25% and a debt-to-equity ratio of 0.46.
Zydus Lifesciences Ltd Share Price Chart — NSE/BSE Historical Performance
Zydus Lifesciences Ltd share price chart: 19.50% return over the past month. 52-week high ₹1115.50, 52-week low ₹835.50.
Zydus Lifesciences Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1082.00 | ₹1091.10 | ₹1061.10 | ₹1078.30 | 19.28L (Cr) | |
| ₹1081.00 | ₹1108.90 | ₹1071.80 | ₹1091.20 | 20.46L (Cr) | |
| ₹1096.45 | ₹1115.50 | ₹1071.20 | ₹1077.70 | 45.88L (Cr) | |
| ₹1085.80 | ₹1085.80 | ₹1085.80 | ₹1085.80 | 0.00 (Cr) | |
| ₹1078.60 | ₹1088.90 | ₹1074.25 | ₹1085.80 | 21.17L (Cr) | |
| ₹1074.00 | ₹1083.25 | ₹1066.35 | ₹1079.05 | 19.49L (Cr) | |
| ₹1049.80 | ₹1075.00 | ₹1041.50 | ₹1072.95 | 23.55L (Cr) | |
| ₹1041.00 | ₹1047.45 | ₹1036.80 | ₹1038.95 | 12.96L (Cr) | |
| ₹1054.00 | ₹1054.00 | ₹1030.05 | ₹1036.45 | 19.21L (Cr) | |
| ₹1066.15 | ₹1093.65 | ₹1038.05 | ₹1040.85 | 135.03L (Cr) |
Zydus Lifesciences Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1081.00 | ₹1108.90 | ₹1061.10 | ₹1078.30 | -0.25% | |
| ₹895.00 | ₹1115.50 | ₹893.15 | ₹1077.70 | +20.41% | |
| ₹888.00 | ₹962.90 | ₹835.50 | ₹891.90 | +0.44% | |
| ₹893.65 | ₹936.15 | ₹858.00 | ₹871.20 | -2.51% | |
| ₹876.30 | ₹947.55 | ₹863.65 | ₹921.70 | +5.18% | |
| ₹919.80 | ₹941.00 | ₹855.95 | ₹885.30 | -3.75% | |
| ₹942.10 | ₹947.00 | ₹896.75 | ₹914.35 | -2.95% | |
| ₹970.50 | ₹998.00 | ₹920.50 | ₹942.50 | -2.89% | |
| ₹981.00 | ₹1017.15 | ₹973.50 | ₹974.45 | -0.67% | |
| ₹988.00 | ₹1059.05 | ₹972.70 | ₹981.90 | -0.62% | |
| ₹970.00 | ₹1029.50 | ₹919.05 | ₹981.05 | +1.14% | |
| ₹974.00 | ₹1000.20 | ₹951.55 | ₹969.80 | -0.43% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Zydus is betting on a US specialty pharma pivot, but execution is key amid generics headwinds.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Zydus Lifesciences' stock is up 1.73% today, quoting on the NSE, rising for the fifth straight session. However, it has slipped around 1.74% in the last month. On April 8, 2026, the company announced it had received FDA approval for its generic dapagliflozin tablets (5mg and 10mg), targeting a market with annual sales exceeding $10 billion.
CORE STORY (THE REAL GAME)
Zydus is transitioning from a generics player to a specialty pharma and biologics company, focusing on the US market and high-value segments like biosimilars and complex generics. The market is watching to see if Zydus can successfully execute this transition and achieve sustainable, high-margin growth.
- FDA approval for Dapagliflozin targets a $10B market
- Indian pharma exports are growing, providing a tailwind
- Strategic acquisitions are expanding manufacturing capabilities
- Successful launch of Dapagliflozin in the US
- Positive outcome from US FDA filing for Saroglitazar Magnesium
- Further strategic acquisitions to expand product portfolio
- Generics pricing pressure in the US
- Delayed FDA approval for biosimilar Saroglitazar
- Potential revenue impact from Asacol HD generics competition
FII increased their stake by 0.21% while DII decreased by 0.23% [cite: brief].
Indian pharma sector projected to reach $130 billion by 2030, driven by global demand.
Yes, Free Cash Flow 5Y: ₹12623.1 Cr [cite: brief].
Zydus aims to strengthen its position in the US market through new product launches and strategic acquisitions. Success hinges on navigating regulatory hurdles and competitive pressures.
Primary Thesis Risk
Failure to successfully transition to specialty pharma and biologics will crush the valuation.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Zydus Lifesciences Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zydus Lifesciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZYDUSLIFE across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (21.25%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.14%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.45%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 21.26 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (21.92%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.22%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (12.45% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (19.18% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (18.77% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (17.26x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹9700.70 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Zydus Lifesciences Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Zydus Lifesciences Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Zydus Lifesciences LtdZydus Lifescien...Selected✓ ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹7273.00₹7273 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1438.00₹1438 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2493.00₹2493 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2543.10₹2543 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1229.50₹1230 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1550.20₹1550 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1554.30₹1554 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹434.60₹435 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 54/100 | ₹5659.00₹5659 | ₹67699.90₹67699.90 | 27.79Average 27.8 Average | 18.88%Good 18.88% Good | 21.23%Excellent 21.23% Excellent | 0.15Excellent 0.1 Excellent | 9.39%Good 9.39% Good | 10.66%Good 10.66% Good | 0.80% |
Glenmark Pharmaceuticals LtdGlenmark Pharma... GLENMARK • 532296 | 70.7/100 | ₹2297.40₹2297 | ₹64821.57₹64821.57 | 21.96Average 22.0 Average | 30.49%Excellent 30.49% Excellent | 39.77%Excellent 39.77% Excellent | 0.06Excellent 0.1 Excellent | 25.68%Excellent 25.68% Excellent | 9.19%Good 9.19% Good | 0.11% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Divis Laboratories Ltd share price193163.97 Cr
- Cipla Ltd share price116131.81 Cr
- Lupin Ltd share price113976.53 Cr
- Mankind Pharma Ltd share price105053.91 Cr
- Dr Reddys Laboratories Ltd share price102660.46 Cr
Zydus Lifesciences Ltd PE Ratio History
Historical price-to-earnings ratio for ZYDUSLIFE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹44.97 | ₹914.35 | 20.3x |
| FY 2024 | ₹38.14 | ₹971.70 | 25.5x |
| FY 2023 | ₹19.30 | ₹689.20 | 35.7x |
| FY 2022 | ₹43.83 | ₹419.95 | 9.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Zydus Lifesciences Ltd Dividend History
Annual cash dividends paid by ZYDUSLIFE — dividend yield 0.09%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹302.50 Cr |
| FY 2024 | ₹621.00 Cr |
| FY 2023 | ₹267.10 Cr |
| FY 2022 | ₹372.20 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Zydus Lifesciences Ltd Quarterly Performance
Latest quarterly metrics for ZYDUSLIFE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
16.22%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
21.92%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.45%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
18.77%
Compounded annual net profit growth over 5 years
Zydus Lifesciences Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ZYDUSLIFE — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Zydus Lifesciences Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Zydus Lifesciences Ltd (ZYDUSLIFE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Zydus Lifesciences Ltd
About ZYDUSLIFE (Zydus Lifesciences Ltd)
Zydus Lifesciences Ltd is a global pharmaceutical powerhouse, deeply rooted in innovation and driven by a commitment to enhancing global health. The company meticulously researches..., develops, manufactures, and distributes a wide spectrum of pharmaceutical products catering to diverse therapeutic areas. With a strong presence in India, the United States, and numerous international markets, Zydus Lifesciences is dedicated to addressing unmet medical needs and improving patient outcomes worldwide. Their infrastructure supports end-to-end pharmaceutical solutions, from drug discovery to commercialization, ensuring quality and accessibility across its product range. They are constantly striving to improve health outcomes and the quality of life across the globe. The organization operates through distinct divisions focused on Pharmaceuticals, which are its central activity. They make active pharmaceutical ingredients, finished formulas for doses, generics, biosimilars, novel products, and specialty products. It also has a division dedicated to Consumer Products. This dual focus allows Zydus Lifesciences to leverage its scientific expertise to create both prescription medications and over-the-counter healthcare solutions. The company's dedication to research and development is evident in its consistent introduction of innovative products and therapies. Zydus Lifesciences distinguishes itself through its dedication to quality, safety, and affordability, making it a trusted partner in healthcare. Zydus Lifesciences extends its reach beyond prescription medications through a well-established portfolio of well-known consumer brands. These include brands in personal care, food and nutrition, and everyday health. These product lines, which include personal care products, nutritional supplements, and wellness goods, reflect the company's comprehensive approach to health and well-being. They are dedicated to providing accessible and high-quality options to consumers. Through this multi-pronged strategy, Zydus Lifesciences continues to expand its footprint in the healthcare industry, further solidifying its position as a leading and responsible global healthcare provider.
Company Details
Key Leadership
Corporate Events
Latest News
ZYDUSLIFE Share Price: Frequently Asked Questions
What is the current share price of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd (ZYDUSLIFE) trades at ₹1078.30 on NSE and BSE. Market cap ₹1.15L (Cr). Educational data only.
What is the P/E ratio of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a P/E of 21.26x vs industry average 34.89x.
What is the Bull Run score for Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a Bull Run score of 74.1/100 based on 25+ financial parameters.
Does Zydus Lifesciences Ltd pay dividends?
Zydus Lifesciences Ltd has a dividend yield of 0.09%. Past dividends don't guarantee future payments.
What is the ROE of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has ROE of 21.25%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has debt-to-equity of 0.46.
Is Zydus Lifesciences Ltd a good investment?
Bull Run gives Zydus Lifesciences Ltd a score of 74.1/100. This is not investment advice — consult a SEBI-registered advisor.